Waters Empowers Advantar Laboratories for Sustained Growth

Waters Corporation has announced that its customer Advantar Laboratories, Inc. (San Diego, CA) has successfully completed its rollout of Waters® Empower™ 3 Chromatography Software.

The 21CFR Part 11 compliant-ready software will play a key role at Advantar and with its new Method Remediation Services group to meet increased demand by pharmaceutical and contract manufacturing customers for converting legacy HPLC methods to Ultra Performance LC® (UPLC®) methods, which offer greater speed, resolution and sensitivity.

Advantar selected Empower 3 software to control its expanding portfolio of gas chromatography (GC), high performance liquid chromatography (HPLC) and UPLC systems with advanced detectors including Waters single and tandem quadrupole mass spectrometry (MS/MS), photodiode array and ultraviolet detectors.

Waters Empower 3 chromatography software bridges the various technologies at Advantar and enables the company to scale its analytical lab resources efficiently.

“Our decision to go with Waters was driven by several key factors including requests from customers. By adding UPLC technology to our lab and creating the Method Remediation Services group, we can support clients who need to develop a UPLC method or rapidly convert multiple methods from HPLC to UPLC simultaneously for large and small molecules alike,” said Advantar Vice President of Sales & Marketing, Brandon Griffin.

“We strongly believe UPLC is the future of chromatography because it greatly reduces run times and solvent waste while significantly improving peak resolution, sensitivity and speed. These benefits translate into tremendous environmental, time and material cost savings for laboratories,” said Rohit Khanna, Ph.D., Vice President of Worldwide Marketing, Waters Division.

Khanna continued, ”For our global base of clients, our UPLC technology continues to support their product development and manufacturing efforts.”

Advantar is now well-equipped to support pharmaceutical companies and contract manufacturers of proprietary and/or off-patent drug products, by leveraging UPLC technology to enhance quality systems for time-critical release testing as well as method development/method transfer needs.